These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 25620749)

  • 1. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
    Goldsweig BK; Carpenter TO
    Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 23 and its receptors.
    Yu X; White KE
    Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia.
    Feng JQ; Clinkenbeard EL; Yuan B; White KE; Drezner MK
    Bone; 2013 Jun; 54(2):213-21. PubMed ID: 23403405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
    Michigami T
    Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF23 and Associated Disorders of Phosphate Wasting.
    Gohil A; Imel EA
    Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FGF23 and bone metabolism].
    Ito N; Fukumoto S
    Clin Calcium; 2005 Jul; 15(7):43-8. PubMed ID: 15995295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF23 and disorders of phosphate homeostasis.
    Yu X; White KE
    Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
    Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
    J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
    Liu S; Gupta A; Quarles LD
    Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatonins: From Discovery to Therapeutics.
    Kritmetapak K; Kumar R
    Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets.
    Razali NN; Hwu TT; Thilakavathy K
    J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1009-17. PubMed ID: 25894638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic role of Fgf23 in Dmp1-null mice.
    Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypophosphatemic rickets and short stature.
    Davis K; Imel EA; Kelley J
    J Bone Miner Res; 2024 Aug; 39(7):821-825. PubMed ID: 38988138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic basis of hereditary hypophosphataemic rickets and phenotype presentation in children and adults.
    Tavana N; Thilakavathy K; Kennerson ML; Ting TH
    Endokrynol Pol; 2021; 72(4):366-394. PubMed ID: 34292571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
    Fukumoto S
    Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.